

<

>

UR “ ”

,

■

93

378

5 474

8.8%

39

5600

13.96%

4.4%

Merck Glaxo

35%

가가

10 (: %)						
	가					
		1993 100 ()		1992 ()		1993 ()
1	Merck()	8,214(6.57)		5,648(4.52)		2,060
2	Glaxo()	7,986(6.39)		3,988(3.19)		1,440
3	BMS()	6,313(5.05)		2,437(1.95)		1,380
4	Hoechst()	6,042(4.83)		2,388(1.91)		1,283
5	Ciba()	5,192(4.15)		2,360(1.89)		1,250
6	SB()	5,100(4.08)		2,186(1.75)		1,020
7	Roche()	4,897(3.92)		2,116(1.69)		1,020
8	Sandoz()	4,885(3.91)		2,040(1.63)		1,010
9	Bayer()	4,670(3.74)		2,013(1.61)		1,010
10	AHP()	4,589(3.67)	가	1,432(1.14)		985

, Pipeline Product , UR

1984

가 , KGMP

가

가

20

92

520

3.1%

50

20

3959

11.2%

■

2

가 30%

가

가

가

15~20%

10

가 15

· EC

EFTA 가

9000 , 92 Merck가 82 1000 , Glaxo가 79
5647 93

10	R&D	(1991) (: 100 , %)
	*1 R&D	
Glaxo	1,052.7	4000 7,247.0 14.5
Roche	953.3	3500 4,119.9 23.1
BMS	845.0	2300 5,908.0 14.3
Hoechst	785.8	4300 6,263.9 12.5
Bayer	688.8	2700 5,306.4 13.0
Ciba-Gaigy	677.8	4200 4,052.3 16.7
Sandoz	675.0	2800 4,440.7 15.2
SB	654.6	5100 4,370.1 15.0
Johnson & Johnson	569.0	2800 3,795.0 15.0
	462.8	3500 2,534.5 18.3

) *89

	(1981 ~ 91) (: %)
	139.5 26.2
	130 24.4
	44 8.3
	43 8.1
	41 7.7
	34 6.7
	30.5 5.7
	13 2.4
	11 2.1
	9 1.7
	6 1.1
가	5 0.8
	4 0.8
1 3	532 100.0

< 1994/4/18 >